Need professional-grade analysis? Visit stockanalysis.com
$3.21B
10.00
704
N/A
Galapagos NV (GLPGF) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $33.27.
Over the past year, GLPGF has traded between a low of $22.39 and a high of $34.00. The stock has gained 48.6% over this period. It is currently 48.6% above its 52-week low.
Galapagos NV has a market capitalization of $3.21B, with a price-to-earnings ratio of 10.00.
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Side-by-side comparison against top Healthcare peers.